Skip to content

Trial Examining Methods for Antidepressant Discontinuation (TEMPO)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511997-66-00
Enrollment
200
Registered
2024-11-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

Rate of failure to successfully discontinue antidepressant: defined as significant deviation from discontinuation antidepressant protocol (e.g. switching to rescue medication (≥5 days in total), stopping with discontinuation medication) or significant withdrawal symptoms (increase in modified 15-item DESS from baseline ≥4 for ≥2 consecutive assessments) during Phase II.

Interventions

DRUGPAROXETINE
DRUGVENLAFAXINE

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Rate of failure to successfully discontinue antidepressant: defined as significant deviation from discontinuation antidepressant protocol (e.g. switching to rescue medication (≥5 days in total), stopping with discontinuation medication) or significant withdrawal symptoms (increase in modified 15-item DESS from baseline ≥4 for ≥2 consecutive assessments) during Phase II.

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026